DESIGN THERAPEUTICS INC. - COMMON STOCK

Design Therapeutics to Participate in Multiple Upcoming Investor Conferences

13 Nov 2024 07:00:49 By Nasdaq GlobeNewswire

Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio

07 Nov 2024 15:01:00 By Nasdaq GlobeNewswire

Design Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

10 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ Portfolio

05 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones

08 May 2024 15:05:01 By Nasdaq GlobeNewswire

Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference

07 May 2024 05:30:00 By Nasdaq GlobeNewswire

Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results

19 Mar 2024 15:01:00 By Nasdaq GlobeNewswire

Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update

12 Mar 2024 05:30:00 By Nasdaq GlobeNewswire

Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024

13 Nov 2023 15:05:00 By Nasdaq GlobeNewswire

Design Therapeutics Provides Pipeline Update and Reports Second Quarter 2023 Financial Results

14 Aug 2023 15:05:00 By Nasdaq GlobeNewswire

Design Therapeutics Reports Initial Results from Phase 1 Multiple-Ascending Dose Study of DT-216 for the Treatment of Friedrich Ataxia

14 Aug 2023 15:01:00 By Nasdaq GlobeNewswire

Design Therapeutics to Present at the 2023 Jefferies Healthcare Conference

31 May 2023 05:30:00 By Nasdaq GlobeNewswire

Design Therapeutics Provides Pipeline Updates and Reports First Quarter 2023 Financial Results

09 May 2023 15:05:01 By Nasdaq GlobeNewswire

Design Therapeutics to Present Preclinical Data on its GeneTAC™ Small Molecule, DT-168, for the Treatment of Fuchs Endothelial Corneal Dystrophy at ARVO 2023

24 Apr 2023 05:30:00 By Nasdaq GlobeNewswire

Design Therapeutics Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results

14 Mar 2023 15:05:00 By Nasdaq GlobeNewswire

Design Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference

08 Feb 2023 05:30:00 By Nasdaq GlobeNewswire

Design Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio Progress

07 Dec 2022 15:01:00 By Nasdaq GlobeNewswire

Design Therapeutics Highlights Pipeline Progress and Upcoming Milestones and Reports Third Quarter 2022 Financial Results

03 Nov 2022 15:05:02 By Nasdaq GlobeNewswire

Design Therapeutics to Present Preclinical Data Highlighting the Potential of its GeneTAC™ Small Molecule, DT-216, for the Treatment of Friedreich Ataxia at ICAR 2022

17 Oct 2022 15:05:00 By Nasdaq GlobeNewswire

Design Therapeutics to Present at the 2022 Jefferies Cell and Genetic Medicine Summit

22 Sep 2022 05:30:00 By Nasdaq GlobeNewswire